Suppr超能文献

用 H. hepaticus、金黄色葡萄球菌和 R. pneumotropicus 进行实验定植不会影响野生型 SOPF 小鼠对高脂肪饮食或肠降血糖素类似物的代谢反应。

Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice.

机构信息

Core Facility Laboratory Animal Services, Helmholtz Munich, Germany.

Core Facility Laboratory Animal Services, Helmholtz Munich, Germany.

出版信息

Mol Metab. 2024 Sep;87:101992. doi: 10.1016/j.molmet.2024.101992. Epub 2024 Jul 15.

Abstract

OBJECTIVES

We here assessed whether typical pathogens of laboratory mice affect the development of diet-induced obesity and glucose intolerance, and whether colonization affects the efficacy of the GLP-1R agonist liraglutide and of the GLP-1/GIP co-agonist MAR709 to treat obesity and diabetes.

METHODS

Male C57BL/6J mice were experimentally infected with Helicobacter hepaticus, Rodentibacter pneumotropicus and Staphylococcus aureus and compared to a group of uninfected specific and opportunistic pathogen free (SOPF) mice. The development of diet-induced obesity and glucose intolerance was monitored over a period of 26 weeks. To study the influence of pathogens on drug treatment, mice were then subjected for 6 days daily treatment with either the GLP-1 receptor agonist liraglutide or the GLP-1/GIP co-agonist MAR709.

RESULTS

Colonized mice did not differ from SOPF controls regarding HFD-induced body weight gain, food intake, body composition, glycemic control, or responsiveness to treatment with liraglutide or the GLP-1/GIP co-agonist MAR709.

CONCLUSIONS

We conclude that the occurrence of H. hepaticus, R. pneumotropicus and S. aureus does neither affect the development of diet-induced obesity or type 2 diabetes, nor the efficacy of GLP-1-based drugs to decrease body weight and to improve glucose control in mice.

摘要

目的

我们在此评估实验室小鼠的常见病原体是否会影响饮食诱导肥胖和葡萄糖耐量受损的发生,以及定植是否会影响 GLP-1R 激动剂利拉鲁肽和 GLP-1/GIP 双重激动剂 MAR709 治疗肥胖和糖尿病的疗效。

方法

雄性 C57BL/6J 小鼠经实验感染嗜肝螺杆菌、肺炎链球菌和金黄色葡萄球菌,并与一组未感染特定和机会致病菌(SOPF)的小鼠进行比较。监测了 26 周的饮食诱导肥胖和葡萄糖耐量受损的发展情况。为了研究病原体对药物治疗的影响,然后对小鼠进行 6 天的每日治疗,给予 GLP-1 受体激动剂利拉鲁肽或 GLP-1/GIP 双重激动剂 MAR709。

结果

定植小鼠与 SOPF 对照在高脂肪饮食诱导的体重增加、食物摄入、身体成分、血糖控制或对利拉鲁肽或 GLP-1/GIP 双重激动剂 MAR709的治疗反应方面没有差异。

结论

我们的结论是,嗜肝螺杆菌、肺炎链球菌和金黄色葡萄球菌的发生既不会影响饮食诱导肥胖或 2 型糖尿病的发生,也不会影响 GLP-1 类药物降低体重和改善葡萄糖控制的疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验